Open in interactive viewer → charts, metric popovers & call review

Hemab's Debut: A Phase III the FDA Didn't Ask For

On its first ever earnings call, a $1.8B rare-disease biotech chose a single-arm pivotal trial over the FDA's preferred randomized design — and staked the equity story on two programs still years behind it.
COAG · Earnings Call · 2026-11-10

The first call is the only call

Hemab Therapeutics went public in May 2026 and used its inaugural quarterly call this week to compress about three years of normal biotech narrative into twenty minutes: a pivotal trial initiated, three data readouts dated, a first clinical dataset in a second indication, and a candid disclosure that the FDA had asked for something the company decided not to give it. There is no prior transcript to hold this management team against — the company's entire curated keyword history is a single quarter, so everything here is new by construction. That makes the exercise simpler and, oddly, more revealing: with no baseline of its own, Hemab's language can only be benchmarked against the rest of the market, and against the logic of its own trial design. The lexicon that surfaced from this call reads less like a commercial story than like the minutes of a regulatory negotiation. Alongside the program names — SOLARA, sutacimig, HMB-002, HMB-003 — the highest-momentum terms were variability, controlled trial, single arm, and eligibility criteria. For a company whose lead asset has no approved competitor, that is exactly backwards from what you would expect a debut call to sound like.

A pivotal trial in the FDA's blind spot

The news itself is real. Monday brought initiation of SOLARA, a Phase III in Glanzmann thrombasthenia — roughly 75 patients, aged 12 to 70, at least four treated bleeds in the prior year, a 24-week run-in followed by 48 weeks of once-weekly subcutaneous dosing at 0.2 mg/kg. It is, per management, the first pivotal trial of a subcutaneous prophylactic in the disease. CEO Benny Sorensen framed the gap bluntly: “There is no approved prophylactic treatment and care today is reactive rather than preventive.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 In the Glanzmann's 360 natural history study cited on the call, 88% of participants reported at least one bleed in the previous week. But the design is a single-arm, open-label study with each patient as their own control, and the company volunteered that the FDA recommended a randomized controlled trial instead. Sorensen's read: “I think when they are saying recommend consider, that is probably for good order.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 He then asserted "the risk is very low here." That is the central tension of this report, and it is not a small one. The company's own Phase II extension — 34 participants, median 6.9 months of exposure, up to 15.9 months — reduced mean high-intensity annualized treated bleed rates by 62%, and roughly 80% in the low-dose weekly cohort. Those are strong numbers. But the same dataset is what management uses to justify avoiding randomization, because the treated bleed rate is so noisy that a parallel-arm design risks being unreadable at this population size. The argument cuts both ways: the variability that makes randomization impractical is also what an intra-patient comparison must survive across dozens of heterogeneous sites.

When we do a Phase II trial in about 15, 16 sites, you get that variability. When we dial it up to a pivotal trial with approximately 75 patients enrolled across multiple countries, multiple sites, variability is rarely going down. It is more likely to stay the same.

Benny Sorensen, Chief Executive Officer · 2026-11-10
Sorensen leaned on precedent — Vonvendi and Wilate in Von Willebrand disease, Hemlibra-adjacent HYMPAVZI in hemophilia A, Tretten in Factor XIII deficiency — and the company holds Fast Track Designation plus Breakthrough and Orphan designations, which matters: that exact regulatory status was one of the better-performing themes in the market's 90-day tape, with a cluster of rare-disease names (LLY, IOVA, ARWR, BIIB, VIR, LGND) up double digits on it. Approval pathways, not just data, are being paid for right now. One small tell: asked what the trial's top weight cutoff was, the CEO replied, “I forgot what the top weight range is in the eligibility criteria.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 Defensible — the details were going up on clinicaltrials.gov — but on the day you announce your first pivotal trial, and after three Grade 2 thromboembolic events in higher-exposure cohorts forced a dose cut to 0.2 mg/kg, weight eligibility is not an administrative footnote.

The market cap is not in Glanzmann

Here is the part the applause obscured. Sutacimig across both Glanzmann thrombasthenia and Factor VII deficiency addresses, by management's own count, about 10,000 patients in its key markets. Glanzmann is a disease where 1 in a million is the right order of magnitude. The $1.81 billion market cap, against $430.2 million of cash and equivalents at September 30, is not a Glanzmann valuation. It is an option on the two assets behind it. HMB-002 in Von Willebrand disease targets roughly 120,000 diagnosed patients in the same geographies. The Phase I/II data discussed were, in Sorensen's words, above plan: peak increases of about 2.5-fold in both von Willebrand factor and Factor VIII against a 1.5-fold target, durable enough to support monthly dosing, and 8 of 9 evaluable patients with zero treated bleeds in the 28 days post-dose versus a baseline mean annualized rate of 20.1. The differentiating argument is elegant and clinicians will get it instantly — you can measure the drug's effect, the same way hematologists have measured DDAVP response for decades. Part B monthly data at 150 mg, plus 300 mg single-dose data, land at EAHAD in February. HMB-003 goes further out and gets bigger: heavy menstrual bleeding affects more than 23 million women in the United States alone and, per data the company cited from Wellcome Leap, costs the economy close to $100 billion a year in missed work. First clinical data are guided to mid-2027. The efficacy bar management keeps repeating — a 50% reduction in treated bleeds — was defended as “the last, I guess, 45 years of development of drugs for bleeding disorders.” — Benny Sorensen, Chief Executive Officer · 2026-11-10 That is a real bar; it is also the floor, and management said so. This is the structural oddity worth flagging: the pivotal trial, the regulatory risk, and the near-term catalysts all sit in the 10,000-patient indication, while the valuation sits in the 120,000- and 23-million-patient ones. The late stage development trade that has worked across biotech over the past year is a bet on de-risked assets; Hemab is asking investors to underwrite late-stage execution on the smallest market first.

Cash, and what the tape is and isn't saying

Financially there is nothing to argue with. R&D ran $24.6 million against $14.6 million a year earlier, G&A $5.1 million against $2.5 million, and the net loss widened to $27.3 million ($0.58 per share against a pre-IPO $18.04) as the clinical machine scaled. Cash fell only $27.3 million sequentially, to $430.2 million, and the CFO was unequivocal: “We continue to expect our cash to fund operations into 2029.” — Mads Behrndt-Eriksen, Chief Financial Officer · 2026-11-10 No financing overhang, no partnering necessity, and a management team visibly uninterested in selling the VWD asset to fund the rest. What the market context does not supply is a price signal — no usable tape for the name in this window — so the report itself is the event. The broader tape is a poor tailwind: the last 30 days of market theme performance are dominated by consumer, home-improvement and apparel names, with the AI and data-center complex heavily on the decline side. Rare-disease biotech is not where the marginal dollar is going right now, and there is no high unmet need bid lifting all boats. Which leaves the question the call could not answer. Hemab has one shot at a single-arm readout in a disease with no precedent for a prophylactic approval, a safety signal already managed by dose reduction, and a valuation that depends on assets nobody will see data on for three more months.“Innovation is good for patients,” — Benny Sorensen, Chief Executive Officer · 2026-11-10 Sorensen said of competitors in VWD, cheerfully declining to engage. Fair enough — but investors will have to price the trial design before they get to price the innovation.